|
|
Post by sla55 on Jul 8, 2015 7:35:02 GMT -5
www.mintakafoundation.org/our-projects/maternal-health/Many deaths by bleeding could be prevented by an immediate intravenous injection of the drug oxytocin. However, oxytocin is unstable in warm climates and trained staff are not always available to give injections. With MannKind Corporation (USA), we have formulated oxytocin in a dry, stabilized form which can be loaded into a robust, very inexpensive, disposable inhaler, eliminating at the same time the need for injection. Administration by inhalation at last makes treatment possible outside centres with trained medical staff.
|
|
|
|
Post by BD on Jul 8, 2015 9:16:40 GMT -5
Is this the fouth, "mystery" application of TS that has been in development, then?
|
|
|
|
Post by notamnkdmillionaire on Jul 8, 2015 9:54:22 GMT -5
Interesting that the company doesn't list Mannkind as a partner. And as this is a non profit, how exactly is MNKD to profit, if any, from this? Or did MNKD just give the application away like it did with the other two drugs it got rid of to the other small pharmas that were suppose to pay some upfront money that never seemed to materialize.
|
|
|
|
Post by hankscorpio7 on Jul 8, 2015 11:28:24 GMT -5
Isn't this for during/after child birth? So target is hot, undeveloped areas which would probably not pay a premium or have insurance. Looks to be a humanitarian effort. Hope it works, good publicity, probably won't contribute to earnings.
|
|
|
|
Post by suebeeee1 on Jul 8, 2015 12:31:11 GMT -5
I think this is GREAT! It won't do anything for earning (immediately), but it is great work, great publicity and a great mission. Should it work, this may become the standard for the delivery of Oxytocin in the future throughout the world, INCLUDING developed countries. Also, if you look at the mission of Mintaka, they are striving to deliver immunizations as well. This is another place that Mannkind can help with the development of inhaled, stable vaccines! Again, this is a place in which the need can then influence use throughout the world.
While it may be that people in Niger initially benefit greatly from the development of stable, inhaled vaccines, this could again become the eventual norm for the world. When was the last time you had your vaccination updates? Exactly. Most of us don't because we don't want to get stuck for a disease that seems unlikely. Can you imagine a time that we go to our doctors and they just hand us an inhaler and tell us to breathe? Easy peasy!
Our involment with this organization may be HUGE!
|
|
|
|
Post by peppy on Jul 8, 2015 12:42:26 GMT -5
Isn't this for during/after child birth? So target is hot, undeveloped areas which would probably not pay a premium or have insurance. Looks to be a humanitarian effort. Hope it works, good publicity, probably won't contribute to earnings. Somewhere I read, in countries with out the hospitals, and the refrigeration systems needed for oxytocin, there are increased numbers of pregnancies where the mother "bleeds out." Technosphere will not require the same cooling systems. I hope I have that correct.
|
|
|
|
Post by benh on Jul 8, 2015 17:07:11 GMT -5
|
|
|
|
Post by babaoriley on Jul 8, 2015 19:27:07 GMT -5
Isn't this for during/after child birth? So target is hot, undeveloped areas which would probably not pay a premium or have insurance. Looks to be a humanitarian effort. Hope it works, good publicity, probably won't contribute to earnings. Got no problem with this effort, and would like to see MNKD reimbursed zero, or at most, a slight discount to its costs; and I hope MNKD can persuade Sanofi to contribute to the effort as well. Efforts like this will repay us many times over. |
|
|
|
Post by anderson on Jul 9, 2015 10:04:14 GMT -5
Oxytocin's off label use could be very profitable www.ncbi.nlm.nih.gov/pubmed/24503174 . It also has several other valid medical uses. This maybe one of the reasons Martin Shkreli doesnt like MNKD since Retrophin has a Oxytocin nasal spray(http://seekingalpha.com/article/1923811-on-moxie-oxytocin-and-shkreli-the-case-for-retrophin). |
|
|
|
Post by afrizzle on Jul 10, 2015 6:10:03 GMT -5
Speculation only...
Disclosure..I've sold pharma related products to Mintaka
Maybe they're functioning strictly in a buyer/seller relationship, with MannKind functioning as a CMO. If the variation on the standard isn't that difficult and they can get a return on investment, then why not (assuming capacity)
|
|
|
|
Post by cretin11 on Jul 10, 2015 22:32:06 GMT -5
Speculation only... Disclosure..I've sold pharma related products to Mintaka Maybe they're functioning strictly in a buyer/seller relationship, with MannKind functioning as a CMO. If the variation on the standard isn't that difficult and they can get a return on investment, then why not (assuming capacity) If that does happen to be the case, what does it mean for MNKD's bottom line? |
|
|
|
Post by harryx1 on Jul 13, 2015 16:24:52 GMT -5
Phase I Clinical Evaluation of Inhaled Oxytocin
|
|
